Introduction
Considerable speculation surrounds the relationship of prolactin secretion to breast cancer (Lancet, 1974) . There are reports of both normal (Bucken et al., 1973; Mittra et al., 1974) and raised (Murray et al., 1972) prolactin concentrations in patients with malignant tumours of the breast. We report here the basal serum prolactin concentrations in a group of patients with cancer of the breast and a comparison of these results with those obtained in women undergoing surgery for what subsequently proved to be benign lesions of the breast.
Patients and Methods
Blood samples were obtained one or two days before operation in a group of 113 inpatients undergoing surgery for a lump in the breast. The diagnosis in all cases was based on histological examination of the excised lesion. Blood samples were allowed to clot at room temperature for two hours and after centrifugation the serum was removed and stored at -20°C until assayed. Prolactin was measured by radioimmunoassay (Sinha et al., 1973) adenomas and one (who was taking the oral contraceptive) had a lump caused by fatty tissue and fibrosis. In contrast, prolactin concentrations were not raised in the 20 other premenopausal patients in this series who had fibroadenomas. Both postmenopausal patients with benign lesions and raised prolactin concentrations had duct ectasia. This histological diagnosis was also made in two other postmenopausal patients whose prolactin concentrations were normal. The one patient with malignant disease and hyperprolactinaemia had an adenocarcinoma.
Discussion
When the patients with benign and malignant diseases of the breast were divided into groups according to their reproductive status there was a significant difference in the incidence of hyperprolactinaemia between the whole group of premenopausal patients and the whole group of postmenopausal patients. It therefore seems important to consider the reproductive status in any study relating to prolactin measurements in patients with benign and malignant disease of the breast.
Our results do not support the theory of an aetiological relationship between hyperprolactinaemia and breast cancer. Furthermore, analysis of the histological findings in the benign lumps in the patients with and without hyperprolactinaemia does not provide support for an aetiological role of prolactin in this condition either.
Finally, it remains to consider the cause of the hyperprolactinaemia in the seven patients who had levels above 25 ng/ml. Pituitary tumours in these patients were unlikely since skull x-ray examinations showed nothing abnormal. None was receiving tranquillizers or other drugs thought to raise prolactin levels. Stress, both physical and psychological (Frantz et al., 1972; Friesen et al., 1972) , can raise prolactin concentrations. Possibly the cause of the hyperprolactinaemia in these patients was the psychological stress associated with the fear of surgery for a lump in the breast. These findings emphasize the need for a strictly matched control group in evaluating hormonal profiles in patients with cancer. We suggest that in the case of carcinoma of the breast patients with benign breast disease form the most 
